Fig. 2: Time to deterioration of PROs for LDAC based patients. | Blood Cancer Journal

Fig. 2: Time to deterioration of PROs for LDAC based patients.

From: Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Fig. 2

Time to deterioration in EORTC GHS/QoL (A), PROMIS Fatigue (B), EORTC PF (C), and Health Status (EQ-5D-5L) VAS (D), VEN + LDAC versus PBO + LDAC. Time to deterioration thresholds for EORTC-QLQ-C30, EQ-5D-5L VAS, and PROMIS Fatigue are ≥10, 7, or 5 points, respectively. Time to deterioration analyses were conducted for all patients in the full dataset with available data on ≥1 PRO measures from baseline to the given assessment (N = VEN + LDAC: 127, 127, 127, and 127; and PBO + LDAC: 59, 60, 59, and 59 for EORTC GHS/QoL, fatigue, PF, and health status VAS, respectively). CI confidence interval, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer quality of life questionnaire, EQ-5D-5L EuroQoL 5-Dimension 5-Level, GHS global health status, LDAC low-dose cytarabine, NE not estimable, PBO placebo, PF physical functioning, PROMIS Patient-Reported Outcomes Measurement Information System, QoL quality of life, VAS visual analog scale, VEN venetoclax.

Back to article page